# of Displayed Technologies: 20 / 25

Applied Category Filter (Click To Remove): Healthcare Portfolios


Categories

Method for diagnosis and prognosis of Alzheimer's disease
TS-050046 — Methods using miRNAs for early Alzheimer’s Disease diagnoses and altered expression of key autophagy related proteins
The Need Alzheimer’s Disease (AD) is the most common cause of age-related dementia leading to severe and irreversible neurodegeneration and cognitive decline. Currently, AD has no cure or effective preventive approaches. Using current diagnostic techniques, AD cannot be clinically diagnosed b…
  • College: College of Medicine (COM)
  • Inventors: Amer, Amal
  • Licensing Officer: Flammang, Ann Marie

Analogues of the Epipolythiodioxopiperazine Alkaloids
TS-047118 — Analogues of verticillin which have more useful drug-like properties than the verticillin parent compounds alone, including increased solubility, absorption, and stability, all while maintaining similar anticancer potency to the original compounds.
Verticillins, which are epipolythiodioxopiperazine (ETP) alkaloids, have shown promising anticancer qualities; these fungal metabolites have exhibited high potency against a variety of tumor cell types, with IC50 values typically in the 10-500 nanomolar range. However, these compounds suffer from …
  • College: College of Pharmacy
  • Inventors: Fuchs, James; Huntsman, Andrew
  • Licensing Officer: Flammang, Ann Marie

Adoptive Transfer of Engineered Macrophages
TS-045881 — The Need Cell therapies have received recent approvals for immunomodulatory indications. Immuno-activating chimeric antigen receptor (CAR)–T cells have been developed for cancers, whereas immunosuppressive mesenchymal stromal cells (MSCs) have been approved for inflammatory bowel disease and …
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Hou, Xucheng; Zhang, Xinfu
  • Licensing Officer: Flammang, Ann Marie

Improved Dressing Design for Insertion Sheaths with Side Ports
TS-044969 — Dressing designed and tailored exclusively for insertion sheaths with side ports, used frequently for pulmonary artery catheters (PACs or Swan-Ganz catheters) among other intravascular devices in the hospital.
The Need Central-line associated blood stream infections (CLABSIs) are a life-threatening and extremely costly problem in hospitals around the world. When patients in the hospital have indwelling catheters such as pulmonary artery catheters, they are at an increased risk of developing such infectio…
  • College: OSU Wexner Medical Center
  • Inventors: Warren, Samantha; Thomas, Jordan
  • Licensing Officer: Flammang, Ann Marie

Biomimetic vitreous substitute with ocular drug delivery
TS-044490 — Methods and compositions for an antioxidant releasing hydrogel vitreous substitute
The vitreous humor is a fragile, transparent tissue between the lens and the retina of the eye that maintains the shape of the eye, acts as a shock absorber, and enables nutrient diffusion to ocular tissues. The vitreous also plays a key role in oxygen homeostasis. Over time, the vitreous degrades…
  • College: College of Engineering (COE)
  • Inventors: Swindle-Reilly, Katelyn; Reilly, Matthew; Tram, Nguyen "Archie"
  • Licensing Officer: Flammang, Ann Marie

Composition and method of lipid nanoparticles carrying oligonucleotides
TS-043629 — Novel lipid nanoparticles used for carrying antisense oligonucleotides with improved targeting for cancer treatment
Lung cancer is the leading cause of cancer related deaths in the US with approximately 150,000 deaths in 2017. Currently, mildly ineffective chemotherapeutics ripe with adverse side effects are the standard treatment. Antisense oligonucleotides (ASOs) are able to selectively modulate expression of…
  • College: College of Pharmacy
  • Inventors: Lee, Robert; Cheng, Xinwei "Evan"
  • Licensing Officer: Flammang, Ann Marie

A Bi-layered Capsule for Sustainable Delivery of Protein Therapeutics
TS-042858 — A biodegradable drug delivery system for the treatment of disease, especially ophthalmic diseases including age-related macular degeneration (AMD). The device will be injected and can control drug release for at least 6 months following the initial injection.
Retinal diseases can be extremely difficult to monitor once procedures have been initiated. AMD is the fourth most common causes of blindness and requires monthly injections to manage the effects of the disease and prevent permanent blindness. However, receiving recurrent injections can potentiall…
  • College: College of Engineering (COE)
  • Inventors: Jiang, Pengfei; Coutinho da Silva, Marco; Lannutti, John; Ohr, Matthew; Swindle-Reilly, Katelyn
  • Licensing Officer: Flammang, Ann Marie

Junctional Tourniquet for Groin and Axillary Regions
TS-041808 — A tourniquet with a ratcheting lock to keep pressure on wounds in the groin and axillary regions. Hemostasis can be achieved while the patient is still in the field.
Patients with blood loss in the field need to be treated immediately to prevent ongoing blood loss, shock, and death; bleeding from extremity and junctional wounds is the leading cause of potentially preventable death from penetrating injuries. Direct manual pressure is effective for the initial c…
  • College: OSU Wexner Medical Center
  • Inventors: McElroy, James; Graham, Nadi; Nocera, Tanya
  • Licensing Officer: Flammang, Ann Marie

Method to improve efficiency and specificity of human tumor targeting and elimination by using a combination of split & splice protein toxins and oncolytic viruses
TS-040838 — Novel strategy to improve efficiency and specificity of tumor treatment via combinative use of a split & splice protein toxin and oncolytic virus.
In combating malignancies as complex as cancer, researchers and clinicians have created a diverse set of strategies to reduce tumor burden. Oncolytic viruses (OVs) have emerged as a promising means of treating this disease due to their potential to selectively target and effectively kill cancer ce…
  • College: College of Arts & Sciences
  • Inventors: Kudryashov, Dmitri; Cripe, Timothy; Kudryashova, Elena; Purde, Vedud
  • Licensing Officer: Flammang, Ann Marie

Multifunctional RNA Nanoparticles and Methods for Treating Cancer
TS-040289 — Three-way junction nanoparticles for delivery of tamoxifen and other therapeutics directly to tumor cells.
Most breast cancers express estrogen receptor alpha (ER α) and antagonists of ER α drugs, such as tamoxifen, have been widely used for their treatment. Unfortunately, up to half of all ER α -positive tumors have intrinsic or acquired endocrine therapy resistance. Recent studies b…
  • College: College of Pharmacy
  • Inventors: Zhang, Xiaoting; Guo, Peixuan
  • Licensing Officer: Flammang, Ann Marie

Novel compositions of nanoparticles for nucleic acid therapeutic delivery
TS-040254 — Novel lipid-based nanoparticles that utilize a surfactant to improve self-assembly and stability. Finalized particles can be used for delivery of nucleic acids such as oligonucleotides and plasmid DNA.
Lipid-based nanoparticles (LNPs) have been extensively utilized in nucleic acid delivery. However, there are a number of challenges associated with LNP formulation. It is difficult to make sub-100-nm LNPs with a high nucleic acid concentration by traditional self-assembly methods. LNP synthesis ty…
  • College: College of Pharmacy
  • Inventors: Lee, Robert
  • Licensing Officer: Flammang, Ann Marie

Productivity model for Advanced Practice Providers
TS-038991 — A new, well-rounded system of measuring APP productivity
Physician assistants (PAs) and nurse practitioners (NPs) are referred to as advanced practice providers (APPs). They are certified health care professionals who provide care and treatment to patients in collaboration with physicians. Although they are an integral part of many clinics and hospitals…
  • College: OSU Wexner Medical Center
  • Inventors: Rosselet, Robin; Cackler, Scott
  • Licensing Officer: Flammang, Ann Marie

Treatment of Multiple Sclerosis with Small Molecule IL-6/STAT3 Inhibitors
TS-038701 — Small-molecule prodrugs that target IL-6/STAT3 signaling pathway.
Multiple Sclerosis (MS), an unpredictable and disabling autoimmune disease affecting the central nervous system, is the leading cause of non-traumatic neurological disability in young adults. There have been important advances in MS therapy, such as drugs that slow the progression of the disease a…
  • College: College of Medicine (COM)
  • Inventors: Yang, Yuhong; Li, Chenglong; Racke, Michael
  • Licensing Officer: Flammang, Ann Marie

Sustained Release Microparticles for the Treatment of Ocular Diseases
TS-038312 — A novel, intravitreal microparticle injection capable of controlled-release of protein therapies (including anti-VEGF) for tunable periods of 6-12 months after injection for the treatment of age-related macular degeneration.
Age-related macular degeneration (AMD) is the leading cause of blindness in individuals 65 and older and is the third leading cause of blindness worldwide. Wet AMD is characterized by abnormal growth of leaky blood vessels leading to damage to the macula of the retina resulting in vision loss and …
  • College: College of Engineering (COE)
  • Inventors: Jiang, Pengfei; Ohr, Matthew; Swindle-Reilly, Katelyn
  • Licensing Officer: Flammang, Ann Marie

Methods for generation of TF-targeting chimeric antigen receptors (CARs)-natural killer cells and T cells
TS-038262 — A therapeutic application of neovascular-targeting chimeric antigen receptor (CAR) T cells and NK cells for treating diseases associated with pathological angiogenesis, in which TF is abarrently expressed, such as solid tumors, leukemia, lymphoma, age-related macular degeneration (AMD), endometriosis, and rheumatoid arthritis.
Nearly 2,000,000 new cancer cases are expected to be diagnosed each year in the United States. Available treatment options include surgery, radiation therapy, chemotherapy, and immunotherapy. Recently, cell-based immunotherapy utilizing specific chimeric antigen receptor (CAR) expressing immune ce…
  • College: College of Medicine (COM)
  • Inventors: Hu, Zhiwei
  • Licensing Officer: Flammang, Ann Marie

Use of Gene Product to Treat Nerve Injury and Sarcopenia
TS-037778 — A novel method using the overexpression of survival motor neuron protein to improve motor unity synaptic repair and restore/protect muscle size and function due to sarcopenia
Sarcopenia, the age-related wasting and loss of strength, is an important neuromuscular problem of aging. It affects up to 50% of individuals by the 8th decade, and can lead to impaired mobility, loss of independence, and increased risk of mortality. The neuromuscular system is comprised of groups…
  • College: College of Medicine (COM)
  • Inventors: Burghes, Arthur; Arnold, William; Kaspar, Brian; McGovern, Vicki
  • Licensing Officer: Flammang, Ann Marie

Thermogenic Compositions and Methods
TS-037747 — Biologicals for treatment of obesity related disease, including glucose intolerance and neurological disorders.
Worldwide obesity has tripled over the last 40 years and the incidence of overweight or obese populations is rising in low, middle, and high income countries. An increase in adipose tissue results in higher risk for cardiovascular disease and type 2 diabetes, which increase risk for Alzheimer&rsqu…
  • College: College of Education & Human Ecology
  • Inventors: Ziouzenkova, Ouliana; Parquette, Jonathan
  • Licensing Officer: Flammang, Ann Marie

Phyllanthusmin and acutissimalignan A compound derivatives for anticancer and immunostimulation
TS-037721 — A group of potential antitumor arylnapthalene lactone derivatives, which may be developed as novel anticancer and immunostimulant agents.
Natural products and semi-synthetic derivatives derived from them have been used for anticancer drugs or drug leads for many years. However, side-effects such as myelosuppression and secondary leukemia have been reported. Furthermore, these natural products can be difficult to use for targeting sp…
  • College: College of Pharmacy
  • Inventors: Kinghorn, Alan "Dr. A. Douglas Kinghorn"; Fuchs, James; Huntsman, Andrew
  • Licensing Officer: Flammang, Ann Marie

STAT3 Inhibitors and Their Anti-Cancer Usage
TS-037671 — Novel non-peptidomimetic molecules for use as anti-cancer inhibitors of signal transducer and activator of transcription 3.
The search for more potent drug delivery candidates for cancer therapy remains a challenge within the medical community. Efforts to target cancer at the genetic level have led to numerous discoveries, including the role that constitutive activation of signal transducer and activator of transcripti…
  • College: College of Pharmacy
  • Inventors: Li, Chenglong; Lin, Jiayuh; Yu, Wenying
  • Licensing Officer: Flammang, Ann Marie

Antisense Morpholino Treatment to Increase SMN Levels and Treat Spinal Muscular Atrophy
TS-037648 — A treatment for spinal muscular atrophy.
Spinal Muscular Atrophy (SMA) is caused by deletion or mutation of SMN1 and retention of SMN2, this in turn leads to reduced levels of the full SMN protein. SMA is the second leading cause of neuromuscular disease, and many people living with SMA need round-the-clock care from their families and a…
  • College: College of Medicine (COM)
  • Inventors: Burghes, Arthur; Porensky, Paul
  • Licensing Officer: Flammang, Ann Marie

Show More Technologies

Loading icon